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We are grateful for the opportunity to respond to the
comments of Viljoen et al.1
The failure of some of their patients to acidify their
urine to a pHo5.3 (the threshold pH described by Wrong
and Davies in the original report of the ‘short NH4Cl
test’2) does not come as a major surprise. It is notable that
Viljoen used the ‘old’ version of the fludrocortisone/
furosemide (Fþ F) test in which fludrocortisone is taken
the preceding night. In an earlier brief report,3 we had
indicated that the ‘old’ Fþ F test appeared to be satis-
factory, when compared with the ‘NH4Cl test’,
2 in a group
of control (healthy) subjects. However, subsequent studies
in our laboratory found that it was not 100% reliable.
For this reason, we abandoned the ‘old’ test and switched
to the ‘new’ Fþ F test, as described in our recent paper,4
in which fludrocortisone and furosemide are given
simultaneously.
Despite Viljoen’s comment concerning the half-life of
fludrocortisone, this modification of the protocol is not a
trivial one. Mounting evidence has emphasized the rapid,
nongenomic properties of mineralocorticoid to stimulate
sodium reabsorption in principal cells (thereby increasing
lumen negativity and indirectly stimulating Hþ secretion)
and to stimulate HþATPase directly in intercalated cells.
ENaC activity in cortical collecting duct principal cells is
increased within 2 min of aldosterone administration,5
transport by basolateral Naþ ,KþATPase is increased
within 30 min,6 and HþATPase activity is increased within
15 min.7 To have these early effects operating at a time
when the distal delivery of sodium has been maximized
by treatment with furosemide may be crucial for the
reliability of the technique in reducing urine pH.
A secondary advantage of the ‘new’ Fþ F test, with
simultaneous dosing of the two drugs on the morning of
the test itself, is that it eliminates the possibility of patient
noncompliance in taking fludrocortisone the preceding
night, a concern that is perhaps heightened owing to the
possibility of sensorineural deafness in some of the
patients.8
Finally, we agree completely that the ‘new’ form of the
test needs rigorous assessment in a variety of patient
subgroups. Although no figures are given in the paper cited
by Viljoen,9 the high prevalence of urinary acidification
defects in stone formers is well known. We have been using
the new Fþ F test routinely as a screening test in our
patients (many of whom are stone formers) for some time.
To date, in each instance in which the Fþ F test has failed
to acidify the patient’s urine despite an absence of other
clinical features consistent with a diagnosis of distal renal
tubular acidosis (e.g., a family history or the presence of
autoimmune disease), a follow-up NH4Cl test has con-
firmed the result. The more we use the new test, the
more confidence we place in it as a screening tool for
distal renal tubular acidosis. It would be of interest to
see how the stone formers in Viljoen’s study respond to
this test.
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Addition of aldosterone receptor
blocker to dual
renin–angiotensin–aldosterone
blockade leads to limitation of
tubulointerstitial injury of kidney
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To the Editor: The inhibition of the renin–angiotensin–
aldosterone system with angiotensin-converting enzyme
inhibitors and angiotensin II type 1 receptor blockers may
retard but not abrogate chronic kidney disease progression.1–3
Additional blockade of the aldosterone receptor as a way to
improve nephroprotection is suggested but not finally
proven.4 In the March issue of Kidney International, Kramer
et al. demonstrated, for the first time, remarkable reduction
in glomerulosclerosis and tubulointerstitial damage after
addition of spironolactone to angiotensin-converting enzyme
inhibitor treatment in proteinuria-induced renal damage
model in rats.5 Here, we present our recent clinical
observations on the same point. In randomized open
controlled crossover study on 18 patients with nondiabetic
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